Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Transport, pharma and biotech as industry become India's biggest research investors
India's private-sector research effort is now being driven overwhelmingly by the transportation, pharmaceutical, biotechnology and information technology industries, with transport companies emerging as the country's largest corporate R&D…
America doesn't have to be Big Pharma's profit center
As former congressmen from opposite sides of the aisle, we rarely agree on healthcare policy. But one thing we do agree on is that, for far too long, the price of healthcare, especially prescription drugs, has been unaffordable for Americans. The…
How a pharma megamerger could squelch R&D
Big drug companies have been buying scrappy biotechs to expand their pipelines, but the potential megamerger between AstraZeneca and Bristol Myers Squibb could flip that script. Why it matters: Combining two drug giants with overlapping portfolios…
Amplia teams up with big pharma for lung cancer trial
Melbourne-based ASX listed biotech Amplia Therapeutics has secured a major collaboration with pharmaceutical goliath Eli Lilly & Company to evaluate a new combination therapy aimed at tackling non-small cell lung cancer (NSCLC). The two companies…
Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite
Piramal Pharma Solutions has added a new spray drying suite with Band 5 containment capacity at its dedicated peptide facility in Turbhe, India, equipped with its own air handling units, nitrogen supply, and control systems. The new suite empowers…
Alembic Pharma Q1 net profit up 12.1% at ₹173.07 cr
Alembic Pharmaceuticals Ltd on Tuesday reported a 12.1 per cent rise in consolidated net profit to ₹173.07 crore in the first quarter ended June on the back of broad-based growth across businesses. The company had posted a consolidated net…
Nuvectis Pharma Target of Unusually Large Options Trading (NASDAQ:NVCT)
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) saw unusually large options trading activity on Tuesday. Investors acquired 3,044 call options on the company. This is an increase of 817% compared to the average volume of 332 call options. A…
Nuvectis Pharma (NASDAQ:NVCT) Issues Earnings Results, Misses Estimates By $0.05 EPS
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.05), FiscalAI reports. NASDAQ:NVCT…
India pharma sector to miss 2030 sales target amid tariff and shipping woes, trade body says
India's pharmaceutical industry is likely to miss its sales target for the end of the decade as U.S. tariff uncertainty and Middle East shipping disruptions weigh on exports, the head of a government-backed trade body told…
Pacer Advisors Inc. Lowers Holdings in Royalty Pharma PLC $RPRX
Pacer Advisors Inc. reduced its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 24.6% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 689,194 shares of…
Eastern Bank Has $38.96 Million Position in Royalty Pharma PLC $RPRX
Eastern Bank lifted its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 5.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 694,925…
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Down After Earnings Miss
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) shares gapped down prior to trading on Tuesday following a weaker than expected earnings announcement. The stock had previously closed at $21.60, but opened at $19.26. Nuvectis Pharma shares…
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Rating of 'Moderate Buy' from Analysts
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have received a consensus rating of 'Moderate Buy' from the twenty-three analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated…
Dimensional Fund Advisors LP Purchases 179,376 Shares of BridgeBio Pharma, Inc. $BBIO
Dimensional Fund Advisors LP increased its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 46.9% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 561,945 shares of…
California State Teachers Retirement System Boosts Stock Position in BridgeBio Pharma, Inc. $BBIO
California State Teachers Retirement System boosted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 23.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The…
Receive a Daily briefing on Pharma Industry News
Get Started